iaslc Home
Home
Featured Topics
Diagnostic Oncology
Early Detection & Screening
Evolving Standards of Care
Global Initiatives
Meeting News
Names & News
Nursing & Allied Health
Patient Advocacy
Radiation Oncology
Regulatory News
Risk Assessment and Reduction
Society News
Supportive & Palliative Care
Surgical Oncology
Tobacco & Smoking Cessation
WCLC News
WCLC News
Featured Industry Events
ATTENDEE MAP & PHOTOS
About Us
Register Now
Menu
Home
Featured Topics
Diagnostic Oncology
Early Detection & Screening
Evolving Standards of Care
Global Initiatives
Meeting News
Names & News
Nursing & Allied Health
Patient Advocacy
Radiation Oncology
Regulatory News
Risk Assessment and Reduction
Society News
Supportive & Palliative Care
Surgical Oncology
Tobacco & Smoking Cessation
WCLC News
WCLC News
Featured Industry Events
ATTENDEE MAP & PHOTOS
About Us
Register Now
Home
Evolving Standards of Care
U.S. Drug Approvals: 2010 – 2020
U.S. Drug Approvals: 2010 – 2020
on:
April 16, 2020
In:
Evolving Standards of Care
Print
Email
Share
0
Tweet
Share
Posted:
April 16, 2020
Tags:
afatinib
alectinib
atezolizumab
brigatinib
ceritinib
crizotinib
dabrafenib
dacomitinib
decade in review
durvalumab
erlotinib
gefitinib
larotrectinib
lorlatinib
necitumumab
nivolumab
osimertinib
pembrolizumab
ramucirumab
trametinib
Share
0
Tweet
Share
About the authors
Related Articles
Neoadjuvant Immunotherapy in NSCLC: A Window of Opportunity Not to Be Missed
July 25, 2023
Adjuvant IO for Operable NSCLC: Where Does It Fit a Changing Landscape?
July 25, 2023
Demystifying AI: How Will Artificial Intelligence Alter the Practice of Thoracic Oncology?
July 25, 2023
Inflammation’s Dark Symphony: Lung Cancer and Depression in Concert
July 25, 2023